Finger-prick test could screen for early Alzheimer’s
Posted: 28 August 2024 GPs could soon be able to screen their patients for Alzheimer’s Disease (AD) using a simple handheld device developed by Monash engineers. Monash engineers have developed the first-of-a-kind finger-prick blood test with ‘needle-in-a hay-stack’…
Life prolonging breast cancer drug receives expanded access on the PBS
Posted: 28 August 2024 Australians diagnosed with a type of metastatic breast cancer will now have access to a life prolonging treatment under the Pharmaceutical Benefits Scheme (PBS) from 1 September 2024. Trastuzumab deruxtecan (Enhertu®) will be expanded on…
$66 million in 10 years: groundbreaking strategic investment fund to drive biomedical innovation
Posted: 28 August 2024 With a grand vision of investing $66 million over 10 years in groundbreaking medical innovations, WEHI’s first strategic investment fund, 66ten, is the largest internal pre-seed and seed fund created by an Australian medical…
Delivery of New Colorectal Cancer Multiplex Assay Alpha Kit
Posted: 28 August 2024 Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (Rhythm or the Company) advises it has received the first batch of the Alpha version of the multiplex antibody detection kits developed and…
Lumos Diagnostics seals deal to advance point-of-care test to monitor liver health
Posted: 27 August 2024 Lumos Diagnostics (ASX:LDX) has extended its existing deal with the Burnet Diagnostics Initiative to progress a new point-of-care test for use in monitoring liver health in an upcoming clinical trial. As part of the deal,…
Sleep tight: New wearable sensor sheds light on getting the best rest
Posted: 27 August 2024 In a world first, a new wearable device developed by Monash University researchers will help to record the impact of artificial light on our bodies for sound sleep, improved mental wellbeing and treating chronic…
Structure of a key “trigger” of the immune response solved
Posted: 27 August 2024 An international collaboration, involving researchers from Monash University and the University of Oxford, has led to a breakthrough in our understanding of how immune responses are started. The study has just been published in Nature. The human…
Florey quantum technology project FeBI on track to transform blood tests for iron disorders
Posted: 27 August 2024 Quantum sensors that will revolutionise diagnosis and management of iron disorders, move to its next phase, thanks to AEA funding. An estimated 1 in 5 women (and 1 in 20 men) in Australia are…
Five Patients Recording a Sustained Reduction in Tumor Size in ACCENT Trial
Posted: 22 August 2024 Amplia Therapeutics Limited is pleased to announce that a fifth patient enrolled in the Company’s Phase 2a clinical trial in pancreatic cancer has recorded a confirmed partial response, meaning a 30% or greater decrease…
Noxopharm Targets Clinical Trial for First-in-Class Drug
Posted: 22 August 2024 Innovative biotech company Noxopharm Limited (ASX:NOX) is pleased to announce its first in-human trial for SOF-SKN™, a novel drug candidate for autoimmune diseases. The trial is planned to start in early calendar year 2025…
Optiscan Signs MOU with University of Minnesota College of Veterinary Medicine
Posted: 22 August 2024 Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘the Company’) is pleased to announce that it has signed a Memorandum of Understanding (MOU) with the prestigious University of Minnesota College of Veterinary Medicine. Under the terms…
INOVIQ Exosome Platform Validated for Parkinson’s Disease EV Isolation
Posted: 22 August 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has further validated its NEURONET™ technology for isolation of brain-derived exosomes in Parkinson’s Disease (PD). On June 24th this year, INOVIQ reported that…
